1. Home
  2. OBIO vs AGEN Comparison

OBIO vs AGEN Comparison

Compare OBIO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • AGEN
  • Stock Information
  • Founded
  • OBIO 2017
  • AGEN 1994
  • Country
  • OBIO United States
  • AGEN United States
  • Employees
  • OBIO N/A
  • AGEN N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OBIO Health Care
  • AGEN Health Care
  • Exchange
  • OBIO Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • OBIO 291.7M
  • AGEN 286.0M
  • IPO Year
  • OBIO N/A
  • AGEN 2000
  • Fundamental
  • Price
  • OBIO $8.28
  • AGEN $15.05
  • Analyst Decision
  • OBIO Strong Buy
  • AGEN Strong Buy
  • Analyst Count
  • OBIO 2
  • AGEN 2
  • Target Price
  • OBIO $17.00
  • AGEN $70.00
  • AVG Volume (30 Days)
  • OBIO 142.4K
  • AGEN 534.1K
  • Earning Date
  • OBIO 08-08-2024
  • AGEN 08-06-2024
  • Dividend Yield
  • OBIO N/A
  • AGEN N/A
  • EPS Growth
  • OBIO N/A
  • AGEN N/A
  • EPS
  • OBIO N/A
  • AGEN N/A
  • Revenue
  • OBIO $2,216,000.00
  • AGEN $161,416,000.00
  • Revenue This Year
  • OBIO $17.90
  • AGEN $43.78
  • Revenue Next Year
  • OBIO $10.51
  • AGEN N/A
  • P/E Ratio
  • OBIO N/A
  • AGEN N/A
  • Revenue Growth
  • OBIO N/A
  • AGEN 69.94
  • 52 Week Low
  • OBIO $4.22
  • AGEN $4.78
  • 52 Week High
  • OBIO $11.69
  • AGEN $38.00
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 59.84
  • AGEN 54.27
  • Support Level
  • OBIO $7.48
  • AGEN $15.05
  • Resistance Level
  • OBIO $8.20
  • AGEN $16.12
  • Average True Range (ATR)
  • OBIO 0.58
  • AGEN 1.14
  • MACD
  • OBIO 0.01
  • AGEN -0.05
  • Stochastic Oscillator
  • OBIO 92.96
  • AGEN 44.11

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: